2023 WCLC Abstract Submission

2023 WCLC Abstract Submissions Are Now Open

Abstract submissions for the 2023 World Conference on Lung Cancer are now open! The WCLC Program Committee invites you to participate by submitting your scientific abstract(s). All submissions will close on April 14th, 2023.
Learn More & Submit Here
bluecommitteenom

2023-2025 Committee Nominations are Now Open

The IASLC seeks a highly talented pool of members to serve as volunteers on its organizational committees to contribute to the effective operation and development of IASLC programs.
Nominate Now
2022 DSA Awards Ceremony

2023 Lectureship & Distinguished Service Awards Nominations

The IASLC Distinguished Service and Lectureship Awards recognize the "luminaries" in lung and thoracic cancers with lifetime achievement awards and IASLC members that are making outstanding contributions to the field.
Nominate Now
2023 WCLC Abstract Submissions Are Now Open
2023-2025 Committee Nominations are Now Open
2023 Lectureship & Distinguished Service Awards Nominations

Homepage

The International Association for the Study of Lung Cancer

The IASLC is a global multidisciplinary organization dedicated to eradication of all forms of lung cancer. From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's members—consisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregivers—are raising the bar for care of patients with lung cancer.

Explore More

Nominations are Open for the IASLC Board of Directors

All IASLC Members are invited to self-nominate to stand for election to serve on the IASLC Board of Directors. The IASLC is committed to diversity in the delivery of its mission. Nominations are due by January 25, 2023.

Submit Your Nomination

ILCN In Focus

ILCN article

Latin America Conference Attendees Gather Face-to-Face for First Time Since 2019

As LALCA 2023 gets under way in Montevideo, Uruguay, hear from chairs Drs. Luis Ubillos, Mario Varangot, Clarissa Mathias, and Carlos Barrios about the science that will be discussed.

Jan 24, 2023
Read more

IASLC POSITION STATEMENT ON TOBACCO CESSATION AFTER A CANCER DIAGNOSIS

Tobacco use is a well-established cause of cancer and contributes to about 1 in 3 cancer deaths. Whereas the harmful effects of smoking on health are well recognized, the negative impacts of continued smoking after a diagnosis of cancer are underappreciated. The substantial body of research reviewed in the 2014 US Surgeon General’s Report concluded that smoking by cancer patients and survivors causes adverse outcomes, including increased overall mortality and cancer-related mortality, greater risk of a second primary cancer, and associations with substantially worse toxicity from cancer treatments. The clinical effects of smoking after a cancer diagnosis also dramatically increase the cost of cancer care. The 2020 US Surgeon General’s Report reported that smoking cessation after a cancer diagnosis is associated with improved survival, and quitting smoking significantly benefits non-cancer-related health outcomes. The recommendations are available in English, Spanish, Portuguese, Japanese, Chinese, and Polish.

Read the Position Statement
Diagnostic Immunochemistry Atlas

THE IASLC ATLAS OF DIAGNOSTIC IMMUNOHISTOCHEMISTRY (IHC)

New Translations of the IASLC IHC Atlas are available! From IHC biochemistry basics to identifying biomarkers, this text provides a comprehensive view of diagnostic IHC in a reader-friendly format. 

Access the IHC Atlas
Language Guide page 1

IASLC Language Guide

In line with the IASLC Equity Statement and in step with the ASCO Language of Respect, we are proud to announce the release of the IASLC Language Guide. The guide was established to instill best practices with commonly used phrases related to patient care. The IASLC will be folding the language found in the guide into all aspects of thoracic oncology education, from abstracts to faculty guidelines to podium presentations. 

Download the Language Guide

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Our Impact

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

See More

Our Work

In Numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.

Lung Cancer Policy Network Map

Provide a global review of lung cancer screening clinical trials, implementation studies, and organized programs. This map facilitates policy-level discussions drawing from real-world implementation around the world and drives a community of learning around LDCT (Low Dose Computed Tomography) screening.
Explore

The IASLC Staging Project

The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer.
Explore more

Pathologic Response (PR) Project

Neoadjuvant therapies have unique advantages and opportunities in lung cancer and need further investigation. Currently, there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice. There is also a lack of precise definitions of the degree of pathologic response, including Major Pathologic Response (MPR) or Complete Pathologic Response (CPR). The IASLC PR Project was created to establish Pathologic Response (PR), Major Pathologic Response (MPR), and/or Complete Pathologic Response (CPR) in surgical resection specimens following neoadjuvant therapies as predictors of long-term clinical benefit in patients with resected stages I to III lung cancers. These recommendations are intended as guidance for clinical trials, although it is hoped they can be viewed as suggestions for good clinical practice outside of clinical trials, to improve the consistency of pathologic assessment of treatment response.
Explore

In numbers

8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide.
45
Years Experience
15K
Number of Research Awards Funded
20.121
JTO Impact Factor
8K+
Members

Upcoming Meetings & Webinars

View all Upcoming Events
IASLC Meeting
Feb 22 - Feb 25 2023
February 2023

IASLC 2023 Targeted Therapies of Lung Cancer Meeting

Open the Site
Endorsed Event
Mar 31 - Apr 02 2023
March 30 - April 1, 2023

Texas Lung Cancer Conference

CME Accredited
Endorsed Event
Mar 29 - Apr 01 2023

2023 European Lung Cancer Congress

JTO-CRR_Hero-0820 - Cropped.jpg

Journal of Thoracic Oncology & JTO Clinical and Research Reports

Lung and thoracic specialists count on the IASLC’s journals to provide perspective on innovation in prevention, detention, diagnosis and cutting-edge treatments. As a leading medical journal, JTO focuses on lung and thoracic cancers and is dedicated to presenting original research reviews and opinions from a wide range of disciplines within the medical community. JTO CRR, the official open access journal of the IASLC, complements the JTO by offering authors a gold open access publication option. 

Explore Our Journals